Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug

Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018. 

US dollars
2017-Founded Harmony Biosciences Raises $270m • Source: Shutterstock

Harmony Biosciences, founded in 2017, has raised $270m via equity investment to pursue novel therapies for sleep and central nervous system disorders; to kick off its portfolio plans the company has acquired US rights to pitolisant from French company, Bioprojet SCR.

Pitolisant, which has recently been approved in Europe under the tradename Wakix for the treatment of narcolepsy in adult patients,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.